Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 8-K (Current Report)
Reporting Date: August 5, 2026 (Event Date)
Transaction Close Date: August 7, 2026
Context: The Company, an emerging growth company incorporated in Delaware, entered into a "reasonable best efforts" public offering to raise capital through the sale of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Aggregate Proceeds: $5,000,000 (or $5,000,285 assuming full exercise of Pre-Funded Warrants), before deducting fees and expenses.
- Securities Issued:
- 996,231 shares of Common Stock.
- Pre-funded warrants to purchase up to 2,849,923 shares of Common Stock.
- Placement Agent Fees: 4.0% of aggregate gross proceeds plus a 1% non-accountable expense allowance and reimbursement of legal/expenses.
- Use of Proceeds: Repayment of outstanding liabilities, potential acquisitions, investments in products/technologies, marketing, and working capital.
- Financial Statements: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's operations.
Material Changes
This filing reports a material definitive agreement and a capital raise event rather than operational performance changes. The primary material change is the increase in outstanding share count and the influx of gross proceeds of approximately $5 million. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
- Management Commentary: Proceeds are intended to support debt repayment, strategic acquisitions, and general working capital needs.
- Risks and Contingencies: The offering was conducted on a "reasonable best efforts" basis. The agreements contain customary representations, warranties, indemnification obligations, and termination provisions.
- Regulatory Status: Securities were sold pursuant to a registration statement on Form S-1 (File No. 333-297001), declared effective on July 30, 2026.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 4.0% placement fee, 1% expense allowance, and other offering costs.
- Review the full text of the Placement Agency Agreement (Exhibit 10.1) and Securities Purchase Agreement (Exhibit 10.2) for specific covenants and termination rights.
- Confirm the dilution impact of the 996,231 new shares and 2,849,923 pre-funded warrants on existing shareholders.
- Check subsequent filings for the actual allocation of proceeds, specifically regarding the repayment of outstanding liabilities.